Get started
IOVANCE BIOTHERAPEUTICS INCIOVANCE BIOTHERAPEUTICS INCIOVANCE BIOTHERAPEUTICS INC

IOVANCE BIOTHERAPEUTICS INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast

1IOVA chart


Full chart

1IOVA upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪509.90 M‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.1404 EUR
Net income (FY)
‪−359.51 M‬ EUR
Revenue (FY)
‪158.49 M‬ EUR
Shares float
‪271.58 M‬
Beta (1Y)
1.65

Employees


Employees (FY)
838
Change (1Y)
+281 +50.45%
Revenue / Employee (1Y)
‪189.13 K‬ EUR
Net income / Employee (1Y)
‪−429.02 K‬ EUR

About Iovance Biotherapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Frederick G. Vogt
Website
iovance.com
Headquarters
San Carlos
Founded
2007
FIGI
BBG01TNY3SD6
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

1IOVA news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Check out other big names from the same industry as 1IOVA.

Frequently Asked Questions


The current price of 1IOVA is 1.5200 EUR — it hasn't changed in the past 24 hours. Watch IOVANCE BIOTHERAPEUTICS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange IOVANCE BIOTHERAPEUTICS INC stocks are traded under the ticker 1IOVA.
1IOVA stock has fallen by −3.87% compared to the previous week, the month change is a −47.20% fall, over the last year IOVANCE BIOTHERAPEUTICS INC has showed a −47.20% decrease.
We've gathered analysts' opinions on IOVANCE BIOTHERAPEUTICS INC future price: according to them, 1IOVA price has a max estimate of 22.35 EUR and a min estimate of 1.79 EUR. Watch 1IOVA chart and read a more detailed IOVANCE BIOTHERAPEUTICS INC stock forecast: see what analysts think of IOVANCE BIOTHERAPEUTICS INC and suggest that you do with its stocks.
1IOVA reached its all-time high on May 8, 2025 with the price of 2.8790 EUR, and its all-time low was 1.5200 EUR and was reached on May 23, 2025. View more price dynamics on 1IOVA chart.
See other stocks reaching their highest and lowest prices.
1IOVA stock is 0.00% volatile and has beta coefficient of 1.65. Track IOVANCE BIOTHERAPEUTICS INC stock price on the chart and check out the list of the most volatile stocks — is IOVANCE BIOTHERAPEUTICS INC there?
Today IOVANCE BIOTHERAPEUTICS INC has the market capitalization of ‪517.50 M‬, it has decreased by −1.44% over the last week.
Yes, you can track IOVANCE BIOTHERAPEUTICS INC financials in yearly and quarterly reports right on TradingView.
IOVANCE BIOTHERAPEUTICS INC is going to release the next earnings report on Aug 7, 2025. Keep track of upcoming events with our Earnings Calendar.
1IOVA earnings for the last quarter are −0.33 EUR per share, whereas the estimation was −0.22 EUR resulting in a −48.93% surprise. The estimated earnings for the next quarter are −0.25 EUR per share. See more details about IOVANCE BIOTHERAPEUTICS INC earnings.
IOVANCE BIOTHERAPEUTICS INC revenue for the last quarter amounts to ‪45.59 M‬ EUR, despite the estimated figure of ‪76.14 M‬ EUR. In the next quarter, revenue is expected to reach ‪59.45 M‬ EUR.
1IOVA net income for the last quarter is ‪−107.37 M‬ EUR, while the quarter before that showed ‪−75.89 M‬ EUR of net income which accounts for −41.49% change. Track more IOVANCE BIOTHERAPEUTICS INC financial stats to get the full picture.
No, 1IOVA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 29, 2025, the company has 838 employees. See our rating of the largest employees — is IOVANCE BIOTHERAPEUTICS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. IOVANCE BIOTHERAPEUTICS INC EBITDA is ‪−327.23 M‬ EUR, and current EBITDA margin is −214.34%. See more stats in IOVANCE BIOTHERAPEUTICS INC financial statements.
Like other stocks, 1IOVA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IOVANCE BIOTHERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.